Caplin Point Laboratories Q1 FY27 Results Analysis: Revenue Jumps 19.6%, US PBT Margin Doubles (CAPLIPOINT)

Cofacto Research Updated August 12, 2026 2 min read

Positive

Caplin Point Laboratories Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 610.36 Cr (+19.60% YoY) and PAT growth of +18.80% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	August 12, 2026
Quarter	Q1 FY 2026-2027
Revenue (Q1)	Rs. 610.36 Cr (+19.60% YoY)
PAT (Q1)	Rs. 179.09 Cr (+18.80% YoY)
EBITDA margin	38.40% (+70 bps YoY)
EPS (Q1)	Rs. 23.27 (+15.80% YoY)
Market cap	Rs. 18,832.17 Cr
CMP	Rs. 2,472.40

Quarter Snapshot

Revenue grew 19.6% YoY, beating the 14-16% guidance, driven by strong US segment growth and margin expansion. EBITDA margin improved to 38.4% with operating leverage, while the US PBT margin more than doubled. Gross margin compression and RoW margin decline are watch items.

Key Investment Insights

Key Positives

Revenue grew 19.6% YoY to Rs.610.36 Cr, above the guided 14-16% range.
EBITDA grew 23.0% YoY to Rs.247.03 Cr with margin expansion to 38.4%.
US segment revenue grew 25.9% YoY to Rs.134.29 Cr, within the 25-30% guidance range.
US segment PBT margin doubled from 9.2% to 24.8% YoY, demonstrating scaling benefits.
Free cash reserves increased to Rs.1,502 Cr from Rs.1,471 Cr, reflecting strong cash generation.

Risk Factors

Gross margin contracted from 61.7% to 59.8% YoY due to inventory build and cost pressures.
Rest of World segment PBT margin declined from 37.5% to 33.3% YoY, pressured by product mix and tender business.
Employee costs grew 25.4% YoY, outpacing revenue growth of 19.6%.